Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening and trial matching…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (aapnews.aap.com.au)